Ignite Creation Date:
2025-12-25 @ 1:46 AM
Ignite Modification Date:
2026-03-09 @ 7:17 AM
Study NCT ID:
NCT02509494
Status:
COMPLETED
Last Update Posted:
2022-07-18
First Post:
2015-06-24
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo
Sponsor:
Janssen Vaccines & Prevention B.V.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Ebola Virus Disease | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Vaccine | View |
| None | Ebola | View |
| None | Ebola virus disease | View |
| None | EVD | View |
| None | Hemorrhagic fever | View |
| None | Sierra Leone | View |
| None | Human adenovirus serotype 26 (Ad26) encoding the Ebola virus Mayinga … | View |
| None | Safety | View |
| None | Immunogenicity | View |
| None | Modified Vaccinia Virus Ankara - Bavarian Nordic Filo-vector | View |
| None | (MVA-BN Filo) | View |